References
Greco E. How to prevent Chemotherapy-Induced Cardiotoxicity. EACPR News, Nov 2012.
Greco E, Greco R. Individualising prevention of anthracycline-induced cardiotoxicity in cancer treatment. E-journal of Cardiology Practice, Vol 10, N° 30, 04 Jun 2012.
Greco E, Greco R. A meta-analysis on anticancer drugs cardiotoxicity. European Journal of Heart Failure Supplements ( 2012 ) 11 ( S1 ), S177.
Greco E, Greco R. Chemioterapia e danno cardiovascolare. Italian Journal of Medicine, AB XV Congresso Nazionale FADOI (2010), pp. 65-66.
Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104: 2492–2498.
S.F. Dent, N.A. Graham. First annual Canadian Cardiac Oncology Network conference. Oncology. Vol 18, No 6 (2011).
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-166.
Eschenhagen T, Force T, Ewer M et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13: 1–10.
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013 Apr; 34(15):1102-11.
Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12: 404–410.
Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006; 114: 2474–2481.
Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55: 213–220.
Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258–2262.
